Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 10/20 | 0.60 |
| ▸ | NPC1 | O15118 | 4/20 | 0.59 |
| ▸ | RAB9A | P51151 | 4/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.59 |
| ▸ | MITF | O75030 | 1/20 | 0.59 |
| ▸ | XBP1 | P17861 | 1/20 | 0.59 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.59 |
| ▸ | KLF5 | Q13887 | 1/20 | 0.59 |
| ▸ | TRPV1 | Q8NER1 | 4/20 | 0.54 |
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | TMPRSS4 | Q9NRS4 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | CASP1 | P29466 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13763264 | 0.85 | KDR (0.71) | KDRNPC1RAB9AKDM4EMITF | |
| SCHEMBL4910596 | 0.83 | KDR (0.54) | KDRNPC1RAB9AKDM4EMITF | |
| SCHEMBL4904838 | 0.83 | KDR (0.54) | KDRNPC1RAB9AKDM4EMITF | |
| SCHEMBL4910381 | 0.83 | KDR (0.54) | KDRNPC1RAB9AKDM4EMITF | |
| SCHEMBL4900096 | 0.83 | KDR (0.54) | KDRNPC1RAB9AKDM4EMITF | |
| SCHEMBL4898810 | 0.83 | KDR (0.54) | KDRNPC1RAB9AKDM4EMITF | |
| SCHEMBL13544369 | 0.81 | TRPV1 (0.78) | KDRNPC1RAB9AKDM4EMITF | |
| SCHEMBL846477 | 0.80 | KDR (0.59) | KDRNPC1RAB9AKDM4EMITF | |
| SCHEMBL13544075 | 0.78 | KDR (0.60) | KDRNPC1RAB9AKDM4EMITF | |
| SCHEMBL846516 | 0.77 | TRPV1 (0.65) | KDRNPC1RAB9AKDM4EMITF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080096919-A1 | Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same | RENOVIS, INC. | 2008-04-24 | — | — | US | claimed |
| US-7312233-B2 | Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same | RENOVIS, INC. (US) | 2007-12-25 | — | — | US | claimed |
| EP-1863757-A2 | AMIDE DERIVATIVES AS ION-CHANNEL LIGANDS AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME | Renovis, Inc. (US) | 2007-12-12 | — | — | EP | claimed |
| WO-2006099410-A2 | AMIDE DERIVATIVES AS ION-CHANNEL LIGANDS AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME | RENOVIS, INC. (US) | 2006-09-21 | — | — | WO | claimed |
| US-20060205773-A1 | Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same | EVOTEC AG (DE) | 2006-09-14 | — | — | US | claimed |
| US-20080096919-A1 | Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same | RENOVIS, INC. | 2008-04-24 | — | — | US | disclosed |
| US-20080096919-A1 | Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same | RENOVIS, INC. | 2008-04-24 | — | — | US | disclosed |
| US-20080096919-A1 | Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same | RENOVIS, INC. | 2008-04-24 | — | — | US | disclosed |
| US-7312233-B2 | Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same | RENOVIS, INC. (US) | 2007-12-25 | — | — | US | disclosed |
| US-7312233-B2 | Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same | RENOVIS, INC. (US) | 2007-12-25 | — | — | US | disclosed |
| US-7312233-B2 | Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same | RENOVIS, INC. (US) | 2007-12-25 | — | — | US | disclosed |
| US-20060205773-A1 | Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same | EVOTEC AG (DE) | 2006-09-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060205773-A1 | Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same | TRPV1, TRPA1, TRPV2 | KDR 2423/4885NPC1 959/4885RAB9A 2274/4885 |
| US-20080096919-A1 | Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same | TRPV1, TRPA1, TRPV2 | KDR 2423/4885NPC1 959/4885RAB9A 2274/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.